These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25432176)

  • 21. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
    Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
    Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
    Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
    Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M
    Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
    Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
    Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
    Jones NM; Rowe MR; Shepherd PR; McConnell MJ
    Int J Oncol; 2016 Jul; 49(1):207-16. PubMed ID: 27176780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
    Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
    Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
    Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.
    Jang GB; Hong IS; Kim RJ; Lee SY; Park SJ; Lee ES; Park JH; Yun CH; Chung JU; Lee KJ; Lee HY; Nam JS
    Cancer Res; 2015 Apr; 75(8):1691-702. PubMed ID: 25660951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation.
    Später T; Müller I; Eichler H; Menger MD; Laschke MW; Ampofo E
    Platelets; 2018 May; 29(3):277-287. PubMed ID: 28503993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells].
    Zhou J; Wang CY; Liu T; Wu HS; Zhou F; Xiong JX; Zhao G; Yang M; Yin T; Zhou MT
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2994-8. PubMed ID: 19080079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of FAK kinase activity preferentially targets cancer stem cells.
    Kolev VN; Tam WF; Wright QG; McDermott SP; Vidal CM; Shapiro IM; Xu Q; Wicha MS; Pachter JA; Weaver DT
    Oncotarget; 2017 Aug; 8(31):51733-51747. PubMed ID: 28881682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells.
    Corominas-Faja B; Cuyàs E; Lozano-Sánchez J; Cufí S; Verdura S; Fernández-Arroyo S; Borrás-Linares I; Martin-Castillo B; Martin ÁG; Lupu R; Nonell-Canals A; Sanchez-Martinez M; Micol V; Joven J; Segura-Carretero A; Menendez JA
    Carcinogenesis; 2018 Apr; 39(4):601-613. PubMed ID: 29452350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.